| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3978645 | Bulletin du Cancer | 2013 | 7 Pages |
Abstract
The development of bisphosphonates and anti-RANK/RANKL agents was associated with a better understanding of physiological and pathological processes of bone remodeling. New agents are now developed in this context targeting factors associated with osteoclastogenesis (TGFβ, PTHrP), with signaling pathways activated during bone remodeling (Src, Cathepsin K) or with tumor cells homing into bone (chemokines). This review aims to present the underlying rationale for these developments as well as the clinical results. The emergence of new bone targeting therapies is discussed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Claire Barth, Christophe Massard, Stéphane Vignot,